Table 2.
Association between tissue miR-99a levels and clinicopathological features of breast cancer patients (cohort #1).
| Number (%) | Median (95% CI) | p Value | ||
|---|---|---|---|---|
| Histological subtype, n (%) | ||||
| Luminal | 59 (57.3%) | 27.00 (31.25–55.26) | 0.9783 | |
| TNBC | 30 (29.1%) | 33.65 (25.62–44.83) | ||
| Her 2-enriched | 14 (13.6%) | 18.51 (8.64–93.79) | ||
| Unknown | n.a. | |||
| Grade group, n (%) | ||||
| 1 | 9 (8.7%) | 38.76 (9.45–110.10) | 0.7869 | |
| 2 | 36 (35.0%) | 18.18 (25.27–56.10) | ||
| 3 | 46 (44.7%) | 32.33 (25.31–57.65) | ||
| Unknown | 12 (11.6%) | |||
| Stage | ||||
| Early (I and II) | 75 (72.8%) | 21.38 (29.78–54.31) | 0.8250 | |
| Late (III and IV) | 13 (12.6%) | 35.87 (19.85–43.36) | ||
| Unknown | 15 (14.6%) | |||
| Pathological T stage, n (%) | ||||
| pT1 | 24 (23.3%) | 23.40 (18.43–52.7) | 0.687 | |
| pT2 | 57 (55.3%) | 23.05 (28.32–48.89) | ||
| pT3 | 6 (5.8%) | 24.57 (-61.25–213.1) | ||
| pT4 | 1 (1%) | 54.97 | ||
| Unknown | 15 (14.6%) | |||
| Regional lymph node metastasis, n (%) | ||||
| No | 39 (37.9%) | 18.51 (23.08–64.21) | 0.6279 | |
| Yes | 50 (48.5%) | 33.90 (28.52–49.03) | ||
| Unknown | 14 (13.6) | |||
| TNBC, triple-negative breast cancer; n.a., not applicable | ||||